AstraZeneca AZN announced that the FDA has granted six months of pediatric exclusivity to its Symbicort inhalation aerosol. Symbicort is a combination formulation containing budesonide, an inhaled ...
The pediatric approval was based on the results of the Phase 3 CHASE (ChildHood Asthma Safety and Efficacy) 3 trial. The Food and Drug Administration (FDA) has approved Symbicort (budesonide and ...
AstraZeneca’s aging respiratory giant Symbicort won a coveted pediatric exclusivity nod from the FDA on Wednesday, giving the brand a longer life—and potentially hundreds of millions in additional ...
AstraZeneca PLC AZN announced phase III study results for its well-known product for asthma, Symbicort. The study showed that the drug improves lung function in pediatric asthma patients aged six to ...
(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) SYMBICORT is a combination asthma medication that contains both an inhaled corticosteroid (ICS ...
Advair (fluticasone propionate/salmeterol) and Symbicort (budesonide/formoterol) are brand-name prescription medications. They’re approved by the Food and Drug ...
On November 18, 2005, FDA alerted health care professionals and patients that several long-acting bronchodilator medicines have been associated with possible increased risk of worsening wheezing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results